Induced Pluripotent Stem Cells for Modeling Physiological and Pathological Striated Muscle Complexity

Area of Science:

• Biomedical research
• Regenerative medicine
• Neuroscience

Background:

• Neuromuscular disorders (NMDs) are a diverse group of diseases impacting skeletal muscle, motor neurons, and neuromuscular junctions, often leading to muscle weakness and significantly affecting patients' quality of life.
• Current animal models frequently fail to accurately replicate human NMD phenotypes, highlighting the urgent need for more representative preclinical models.
• Human induced pluripotent stem cells (hiPSC) have emerged as a powerful tool in biomedical research, offering new avenues for studying complex diseases like NMDs.

Purpose of the Study:

• To emphasize the critical need for advanced human preclinical models to study the broad spectrum of NMDs.
• To explore the potential of hiPSC-derived models for characterizing disease variants, investigating gene functions, and developing novel therapeutic strategies for NMDs.
• To identify current challenges and future directions in improving in vitro skeletal muscle maturation for modeling adult-onset muscle diseases.

Main Methods:

• Utilizing patient-derived hiPSC technology to create in vitro models of neuromuscular disorders.
• Investigating skeletal muscle pathophysiology, which involves complex interactions between multinucleated muscle fibers, extracellular matrix, and motor neurons.
• Leveraging bioengineering approaches to enhance the maturation of in vitro muscle tissue.

Main Results:

• hiPSC technology has significantly advanced biomedical research, including the study of NMDs.
• Significant challenges remain in achieving sufficient maturation of in vitro skeletal muscle fibers, particularly for adult-onset conditions.
• Bioengineering applied to hiPSC holds substantial promise for future research in muscle pathophysiology and therapeutic development.

Conclusions:

• Innovative and representative human preclinical models, particularly those derived from hiPSCs, are essential for advancing the understanding and treatment of neuromuscular disorders.
• Overcoming challenges in in vitro muscle maturation is key to effectively modeling and treating adult-onset NMDs, cachexia, and sarcopenia.
• Future advancements in bioengineering will be instrumental in investigating muscle pathophysiology and developing targeted therapeutic strategies for neuromuscular conditions.